Jonathan David Lee

Jonathan David Lee

Auto-generated profile, based on publicly available information

Jonathan David Lee

Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Cell
Verified
Journal Article
Closed access
ABAssaf C. Bester
Assaf C. Bester
JLJonathan D. Lee
Jonathan D. Lee
ACAlejandro Chavez
Alejandro Chavez
YLYu-Ru Lee
Yu-Ru Lee
DNDaphna Nachmani
Daphna Nachmani
PPPier Paolo Pandolfi
Pier Paolo Pandolfi

17 May 2019 in Science
Verified
Journal Article
Closed access
PDF file
YLYu-Ru Lee
Yu-Ru Lee
MCMing Chen
Ming Chen
JLJonathan D. Lee
Jonathan D. Lee
JZJinfang Zhang
Jinfang Zhang
SLShu-Yu Lin
Shu-Yu Lin
PPPier Paolo Pandolfi
Pier Paolo Pandolfi
Supporting tumor suppression: The protein PTEN is a phosphatase and tumor suppressor whose activity is often decreased in human cancers. Thus, reactivating such a protein could potentially be an effective therapy against cancer. Lee et al. identified a ubiquitin E3 ligase (WWP1) as a PTEN-interacting protein that modifies PTEN and inhibits its tumor suppressive activity (see the Perspective by Parsons). Depletion of WWP1 increased dimerization and membrane recruitment of PTEN. A natural compound found to be a pharmacological inhibitor of WWP1 inhibited tumor growth in a mouse model of prostate cancer. Thus, reactivation of the tumor suppressor PTEN may provide a strategy for battling tumors. Science , this issue p. eaau0159 ; see also p. 633

8 July 2016 in Nature Communications
Verified
Journal Article
Open access
CMClint L. Miller
Clint L. Miller
MPMilos Pjanic
Milos Pjanic
TWTing Wang
Ting Wang
TNTrieu Nguyen
Trieu Nguyen
ACAriella Cohain
Ariella Cohain
TQThomas Quertermous
Thomas Quertermous
Coronary artery disease (CAD) is the leading cause of mortality and morbidity, driven by both genetic and environmental risk factors. Meta-analyses of genome-wide association studies have identified >150 loci associated with CAD and myocardial infarction susceptibility in humans. A majority of these variants reside in non-coding regions and are co-inherited with hundreds of candidate regulatory variants, presenting a challenge to elucidate their functions. Herein, we use integrative genomic, epigenomic and transcriptomic profiling of perturbed human coronary artery smooth muscle cells and tissues to begin to identify causal regulatory variation and mechanisms responsible for CAD associations. Using these genome-wide maps, we prioritize 64 candidate variants and perform allele-specific binding and expression analyses at seven top candidate loci: 9p21.3, SMAD3, PDGFD, IL6R, BMP1, CCDC97/TGFB1 and LMOD1. We validate our findings in expression quantitative trait loci cohorts, which together reveal new links between CAD associations and regulatory function in the appropriate disease context.

30 September 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
DNDaphna Nachmani
Daphna Nachmani
ABAnne H. Bothmer
Anne H. Bothmer
SGSilvia Grisendi
Silvia Grisendi
AMAldo Mele
Aldo Mele
DBDietmar Bothmer
Dietmar Bothmer
PPPier Paolo Pandolfi
Pier Paolo Pandolfi

5 December 2022 in Nature Aging
Verified
Journal Article
Open access
PDF file
MMMaria Mavrikaki
Maria Mavrikaki
JLJonathan D. Lee
Jonathan D. Lee
ISIsaac H Solomon
Isaac H Solomon
FSFrank J. Slack
Frank J. Slack
As coronavirus disease 2019 (COVID-19) and aging are both accompanied by cognitive decline, we hypothesized that COVID-19 might lead to molecular signatures similar to aging. We performed whole-transcriptome analysis of the frontal cortex, a critical area for cognitive function, in individuals with COVID-19, age-matched and sex-matched uninfected controls, and uninfected individuals with intensive care unit/ventilator treatment. Our findings indicate that COVID-19 is associated with molecular signatures of brain aging and emphasize the value of neurological follow-up in recovered individuals.

18 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
JLJing Liu
Jing Liu
CTCollin Tokheim
Collin Tokheim
JLJonathan D. Lee
Jonathan D. Lee
WGWenjian Gan
Wenjian Gan
BNBrian J. North
Brian J. North
WWWenyi Wei
Wenyi Wei
Chromosomal rearrangements can generate genetic fusions composed of two distinct gene sequences, many of which have been implicated in tumorigenesis and progression. Our study proposes a model whereby oncogenic gene fusions frequently alter the protein stability of the resulting fusion products, via exchanging protein degradation signal (degron) between gene sequences. Computational analyses of The Cancer Genome Atlas (TCGA) identify 2,406 cases of degron exchange events and reveal an enrichment of oncogene stabilization due to loss of degrons from fusion. Furthermore, we identify and experimentally validate that some recurrent fusions, such as BCR-ABL, CCDC6-RET and PML-RARA fusions, perturb protein stability by exchanging internal degrons. Likewise, we also validate that EGFR or RAF1 fusions can be stabilized by losing a computationally-predicted C-terminal degron. Thus, complementary to enhanced oncogene transcription via promoter swapping, our model of degron loss illustrates another general mechanism for recurrent fusion proteins in driving tumorigenesis.